Ruth March

Vice-President
Gene Therapy
MedImmune
United Kingdom

Business Expert Clinical Research
Biography

  Ruth has pioneered the first FDA-approved lab-based companion diagnostic, the first drug label based on circulating tumour DNA, the first diagnostic partnership for next generation sequencing, and personalised healthcare across therapy areas

Research Intrest

  Ruth has led AstraZeneca’s capability in personalised healthcare to develop as an industry leader, ensuring 80% of drug projects are following personalised healthcare approaches, and steering $90m investment in diagnostic partnerships